par Kourie Hampig, Raphael 
;Klastersky, Jean
Référence Immunotherapy, 8, 7, page (799-807)
Publication Publié, 2016-06
;Klastersky, Jean Référence Immunotherapy, 8, 7, page (799-807)
Publication Publié, 2016-06
Article révisé par les pairs
| Résumé : | The next decade in cancer therapy will be marked by the expansion of immunotherapies, namely immune checkpoint inhibitors. The increasing number and combination of checkpoint inhibitors and the variety of their mechanisms of action and indications will most likely multiply the side effects associated with these therapies and make their management more complicated and diversified. Given the growing rate of approval of different checkpoint inhibitors in different cancers in multiple settings, a review summarizing the major side effects of the new agents in use today and their management seems to be appropriate. Highlighting these adverse events and their management in a single review might help the daily practice of the physicians and consequently contribute the patient's safety and quality of life. |
